Mechanism of Quinolone Action and Resistance
By Katie J. Aldred, R. Kerns, N. Osheroff. Biochemistry, 2014
1,143 citations recorded by the source corpus.
Quinolones are one of the most commonly prescribed classes of antibacterials in the world and are used to treat a variety of bacterial infections in humans. Because of the wide use (and overuse) of these drugs, the number of quinolone-resistant bacterial strains has been growing steadily since the 1990s. As is the case with other antibacterial agents, the rise in quinolone resistance threatens the clinical utility of this important drug class. Quinolones act by converting their targets, gyrase and topoisomerase IV, into toxic enzymes that fragment the bacterial chromosome. This review describes the development of the quinolones as antibacterials, the structure and function of gyrase and topoisomerase IV, and the mechanistic basis for quinolone action against their enzyme targets. It will then discuss the following three mechanisms that decrease the sensitivity of bacterial cells to quinolones. Target-mediated resistance is the most common and clinically significant form of resistance. It is caused by specific mutations in gyrase and topoisomerase IV that weaken interactions between quinolones and these enzymes. Plasmid-mediated resistance results from extrachromosomal elements that encode proteins that disrupt quinolone–enzyme interactions, alter drug metabolism, or increase quinolone efflux. Chromosome-mediated resistance results from the underexpression of porins or the overexpression of cellular efflux pumps, both of which decrease cellular concentrations of quinolones. Finally, this review will discuss recent advancements in our understanding of how quinolones interact with gyrase and topoisomerase IV and how mutations in these enzymes cause resistance. These last findings suggest approaches to designing new drugs that display improved activity against resistant strains.
Subfields: Molecular Biology, Pharmacology, Toxicology
View Paper: https://www.semanticscholar.org/paper/7783421fb01df82c647053843b8779813b57ba38
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pharmacology
Citations in the corpus
- Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022, background): “aeruginosa confers resistance to carbapenems(234) and mutations of DNA gyrase (GyrA) causes resistance to quinolone antibiotics.(257) Importantly, mutations in the β-lactamase gene ampC causes a significant increase in resistance to cephalosporins.”
- Probiotics and competitive exclusion of pathogens in shrimp aquaculture (2020, background): “Interference competition typically involves the production of antimicrobials, which range from strain-specific bacteriocins (ribosomally synthesised antimicrobial peptides; Yang et al., 2014), to broad-spectrum antibiotics such as the quinolones (Aldred et al., 2014).”
- Mechanisms of Antibiotic Resistance (2016, background): “…Qnr-encoding genes has been shown to promote the emergence of highly resistant isolates by facilitating the selection of mutants with point mutations in genes encoding the DNA gyrase and/or topoisomerase IV (56) (the predominant target of the fl uoroquinolone class of antibiotics; see below).”